High-Risk Human Papillomavirus DNA in the Primary Tumor, Sentinel, and Nonsentinel Pelvic Lymph Nodes in Patients With Early-Stage Cervical Cancer A Correlation With Histopathology

被引:15
作者
Slama, Jiri [3 ]
Drazdakova, Marcela [1 ]
Dundr, Pavel [2 ]
Fischerova, Daniela
Zikan, Michal
Pinkavova, Ivana
Freitag, Pavel
Pavlista, David
Zima, Tomas [1 ]
Cibula, David
机构
[1] Charles Univ Prague, Inst Clin Biochem & Lab Diagnost, Sch Med 1, Prague 12851 2, Czech Republic
[2] Charles Univ Prague, Dept Pathol, Sch Med 1, Prague 12851 2, Czech Republic
[3] Charles Univ Prague, Gen Teaching Hosp, Dept Oncogynecol, Sch Med 1, Prague 12851 2, Czech Republic
关键词
Cervical cancer; HPV; Lymph node; Sentinel lymph node; Recurrence; HPV DNA; PROGNOSTIC-SIGNIFICANCE;
D O I
10.1111/IGC.0b013e3181a13186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Metastatic involvement of pelvic lymph nodes is the most important prognostic parameter in early-stage cervical cancer. Still, approximately 15% of patients with negative pelvic nodes experience recurrence, most of them in the pelvis. The presence of human papillomavirus (HPV) DNA in histologically negative pelvic nodes is considered a subclinical metastatic spread. Methods: Patients with early-stage cervical cancer referred for surgical treatment were enrolled in the study. Cytobrush technique was used for sample collection from the fresh tissue to avoid any loss of material for histology. Results: Altogether, 49 patients were enrolled in the study. High-risk (HR) HPV DNA was identified in the tumor in 91.8% patients and in the sentinel node or other pelvic nodes in 49.9% patients. Among the 10 HR HPV genotypes detected, HPV 16 was the most frequently represented in both the tumor and the lymph nodes (66.7% and 7 1.4%, respectively). All metastatic lymph nodes were HR HPV positive. Conclusions: The presence of HR HPV DNA in a sentinel node had a 100% positive predictive value for metastatic involvement of pelvic lymph nodes in Our study. This could be considered a sign of an early subclinical metastatic spread; however, the prognostic value has to be evaluated through a longer follow-up.
引用
收藏
页码:703 / 707
页数:5
相关论文
共 50 条
  • [31] Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy
    Kim, D.
    Ki, Y.
    Kim, W.
    Park, D.
    Suh, D.
    Kim, K.
    Lee, J.
    Jeon, H.
    Nam, J.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2020, 41 (01) : 42 - 47
  • [32] Analysis of the prognostic factors determining the oncological outcomes in patients with high-risk early-stage cervical cancer
    Kilic, Fatih
    Cakir, Caner
    Yuksel, Dilek
    Korkmaz, Vakkas
    Kimyon Comert, Gunsu
    Boran, Nurettin
    Koc, Sevgi
    Turan, Taner
    Turkmen, Osman
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 42 (02) : 281 - 288
  • [33] Cervical injection as an alternative to the utero-ovarian ligament for mapping pelvic sentinel lymph node in early-stage ovarian cancer
    Lago, Victor
    Rey, Iria
    Arnaez, Marta
    Padilla-Iserte, Pablo
    Matute, Luis
    Gurrea, Marta
    Moner, Sara
    Bello, Pilar
    Domingo, Santiago
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025, : 1407 - 1414
  • [34] Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer
    Kocian, Roman
    Kohler, Christhardt
    Bajsova, Sylva
    Jarkovsky, Jiri
    Zapardiel, Ignacio
    Di Martino, Giampaolo
    van Lonkhuijzen, Luc
    Sehnal, Borek
    Sanchez, Octavio Arencibia
    Gil-Ibanez, Blanca
    Martinelli, Fabio
    Presl, Jiri
    Minar, Lubos
    Pilka, Radovan
    Kascak, Peter
    Havelka, Pavel
    Michal, Martin
    van Gorp, Toon
    Nemejcova, Kristyna
    Dundr, Pavel
    Cibula, David
    GYNECOLOGIC ONCOLOGY, 2024, 188 : 83 - 89
  • [35] Micrometastases in Sentinel Lymph Nodes Represent a Significant Negative Prognostic Factor in Early-Stage Cervical Cancer: A Single-Institutional Retrospective Cohort Study
    Kocian, Roman
    Slama, Jiri
    Fischerova, Daniela
    Germanova, Anna
    Burgetova, Andrea
    Dusek, Ladislav
    Dundr, Pavel
    Nemejcova, Kristyna
    Jarkovsky, Jiri
    Sebestova, Silvie
    Fruhauf, Filip
    Dostalek, Lukas
    Ballaschova, Tereza
    Cibula, David
    CANCERS, 2020, 12 (06)
  • [36] The prognosis of high-risk early-stage cervical cancer patients who did not receive postoperative concurrent chemoradiotherapy
    Kuroda, H.
    Mabuchi, S.
    Matsumoto, Y.
    Kozasa, K.
    Sasano, T.
    Takahashi, R.
    Kobayashi, E.
    Kimura, T.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (02) : 225 - 230
  • [37] CPE overexpression is correlated with pelvic lymph node metastasis and poor prognosis in patients with early-stage cervical cancer
    Hong-wei Shen
    Jin-feng Tan
    Jian-hong Shang
    Min-zhi Hou
    Jun Liu
    Li He
    Shu-zhong Yao
    Shan-yang He
    Archives of Gynecology and Obstetrics, 2016, 294 : 333 - 342
  • [38] Prognostic significance of negative conversion of high-risk Human Papillomavirus DNA after treatment in Cervical Cancer patients
    Chen, Qingqing
    Shi, Runjun
    Liu, Zhengcao
    Shi, Zhouhong
    Gu, Ke
    Chen, Jie
    He, Yan
    Li, Ying
    Wu, Jinchang
    Ji, Shengjun
    Zhou, Jundong
    Zhu, Jiahao
    JOURNAL OF CANCER, 2020, 11 (20): : 5911 - 5917
  • [39] CPE overexpression is correlated with pelvic lymph node metastasis and poor prognosis in patients with early-stage cervical cancer
    Shen, Hong-wei
    Tan, Jin-feng
    Shang, Jian-hong
    Hou, Min-zhi
    Liu, Jun
    He, Li
    Yao, Shu-zhong
    He, Shan-yang
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 294 (02) : 333 - 342
  • [40] Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
    Randall, Leslie M.
    Monk, Bradley J.
    Darcy, Kathleen M.
    Tian, Chunqiao
    Burger, Robert A.
    Liao, Shu-Yuan
    Peters, William A.
    Stock, Richard J.
    Fruehauf, John P.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (03) : 583 - 589